Based on its special structure, KIR2DL4 can mediate a complicated cross-talk between immune checkpoint and cytokines in breast cancer microenvironment, and dictate distinct outcome of immunotherapy depending on whether or not HLA-G is engaged. This evidence concerns the gene HLA-G and breast carcinoma.